
Novo Nordisk will take a blow from rising energy costs and an increasing cost pressure due to inflation, according to an analysis from UK-based global healthcare equity research firm Intron heath, which Danish business daily Børsen has seen.
Increasing cost pressure could reduce Novo Nordisk’s profits by nearly 10 percent in 2023, according to Naresh Chouhan, an analyst at Intron Health.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app